Non-intrusive solution for Obstructive Sleep Apnea Syndrome

Descrizione del progetto

Un nuovo test per rilevare l’apnea ostruttiva del sonno

L’apnea ostruttiva del sonno è una condizione associata al collasso delle vie aeree superiori durante il sonno. È causata dall’eccessivo rilassamento dei muscoli che sostengono la gola e la lingua. La diagnosi prevede di trascorrere una notte in un laboratorio del sonno e di sottoporsi a un test di polisonnografia. Gli scienziati del progetto Sleepwise, finanziato dall’UE, hanno sviluppato un approccio meno invasivo per rilevare l’apnea ostruttiva del sonno e altri disturbi legati al sonno e all’epilessia. Il test si basa sull’elaborazione delle immagini durante i periodi di sonno/veglia, non richiede una formazione approfondita e, aspetto ancora più importante, è adatto all’uso nei bambini.

Obiettivo

The Obstructive Sleep Apnea (OSA) is a chronic disease that afflicts approximately 100 million people, however, nearly 80%
of people with this condition remain undiagnosed. Sleep Apnea has serious medical consequences but it is also
economically costly. In the USA alone the estimated economic cost of undiagnosed OSA is $149.6 billion.
The diagnosis of OSA is typically made after a polysomnography (PSG), an expensive test that requires an overnight stay in
a sleep laboratory wired to up to 15 different devices. Today the use of Home Sleep Tests are increasing due to are less
intrusive and cheaper, however, they are subject to patient error in attaching the sensors, require previous training, are
cumbersome and are not appropriate for children.
Tarsio Medics is a technological company that has been working during more than 10 years together with the Pneumology
unit of the Hospital Trias i Pujol to develop SleepWise, an innovative system for the exploration and diagnosis of OSA based
on image processing.
Our patented SleepWise system is non-intrusive, low cost, does not require training. It provides automatic analysis for sleep
professionals, is more reliable because it can infer sleep/awake periods and is more versatile as it can also detect other
nocturnal movements such as restless legs, parasomnias and epilepsy.
We plan to monetize SleepWise offering a complete end-to-end service to doctors, hospitals and health insurance
companies. The market potential is large: the global sleep apnea diagnostic system market is €341.7 €205.06 of them
related with Home Sleep Tests.
Currently we have a beta version of the SleepWise. Now we are applying to the SME Instrument Phase 1 to carry out a
Feasibility Study to assess operational, technological and economic viability as well as to elaborate a Business Plan to
define the business growth, sustainability, exploitation strategies and tactics to follow paving the way to a global market.

Campo scientifico

Programma(i)

Argomento(i)

EIC-SMEInst-2018-2020 - SME instrument

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

TARSIO MEDICS SL

Contribution nette de l'UE

€ 50 000,00

Indirizzo

CALLE DE MAR 15 2-1
08380 MALGRAT DE MAR
Spagna

PMI

Sì

Regione

Este Cataluña Barcelona

Tipo di attività

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Collegamenti

Contatta l’organizzazione

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Costo totale

€ 71 429,00